Abstract
Overview
Introduction
Supportive care can be defined as those products used to prevent and/or treat
the adverse side effects that arise as a result of the tumor itself or
administration of anticancer therapies, in particular cytotoxic chemotherapy.
While the antihormonal therapies and novel molecular targeted therapies do not
exist without some toxicity, these are not as severe as those associated with
chemotherapy.
Scope
- Overview of the current oncology supportive care market, including
profiles of key marketed products and events impacting each during 2006-16
- Examination of the oncology supportive care pipeline with in-depth
clinical and commercial profiles of Phase III and some key Phase II candidates
- Seven-market sales forecasts from 2006 to 2016 for branded oncology
supportive care products and key pipeline candidates
- Detailed discussion of key strategic issues in the oncology supportive
care market, including one commercial impact case study
Report Highlights
The oncology supportive care market is forecast to undergo slightly positive
growth at a CAGR of 0.6%, from a seven-market sales total of $13,763m in 2006
to $14,679m in 2016. This low level of growth is largely due to an increasing
level of patent expiry and generic competition, including the impending launch
of biosimilars in the EU.
The erythropoietins class has come under increasing levels of scrutiny of late
due to emerging doubts over safety of these products. As a result the FDA and
EMEA are recommending more restrictive conditions for use and increased
monitoring of patients. It is expected that sales of these products will
suffer as a result of these restrictions.
Any significant future growth in the oncology supportive care market will
likely come from product development in new indications, such as
EGFR-inhibitor associated skin rash. However, given the early-phase of
clinical development for such products, it will be some time before any impact
is made and true future potential can be determined.
Reasons to Purchase
- Understand market specific drivers and predict the future potential of key
marketed and pipeline oncology supportive care products
- Assess the impact of product launches and identify the opportunities and
risks for key products within the oncology supportive care market
- Adopt knowledge to drive strategic planning for marketed products and
optimize the market penetration of new entrants
| 
View Cart
